Glutamate and Neuropsychiatric Disorders
Springer International Publishing (Verlag)
978-3-030-87479-7 (ISBN)
This volume provides a comprehensive overview of recent advances in targeting glutamate signaling for the treatment of major psychiatric and neurological disorders. It draws on the latest findings in glutamate neurobiology and offers valuable insights into the application of translational principles in neuroscience drug discovery and development.
In each chapter, glutamate as a neurotransmitter, its receptors and transporters, and their interplay with other neurotransmitters and neurotrophic factors, are discussed in the context of a specific, highly prevalent and disabling CNS disease. Most recent and detailed information is provided on Ischemic Stroke, Chronic Stress, Major Depressive Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD), Posttraumatic Stress Disorder (PTSD), Alzheimer's Dementia, Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD), Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple Sclerosis, Parkinson's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders. Moreover, the book includes an extensive overview of glutamatergic treatments already available on the market, and those which are currently in pharmaceutical drug development pipelines.
The primary beneficiaries will be neurology and psychiatry specialists and residents, neuroscientists, neuropharmacologists, pharmaceutical industry and clinical research organization professionals, academics, and clinicians working with psychiatric and neurological patients with comorbidities such as cardiologists, pulmonologists, and endocrinologists. This book will also appeal to psychiatry and neurology subspecialists and clinicians working in neuroscience labs seeking an easy-to-understand yet comprehensive overview of contemporary evidence-based clinical insights backed by basic science (preclinical) research evidence.
lt;p>Dr. Zoran M. Pavlovic focuses his work on consulting pharmaceutical and biotech companies on clinical trial design, methodology, biomarkers and surrogate endpoints, patient-reported outcomes, and psychometric assessments, related to development of their drug candidates for treatment of major psychiatric and neurological disorders.
Dr. Pavlovic's primary interests and expertise have centered on psychopharmacologic approaches to Chronic Stress, Major Depressive and Anxiety disorders, Substance Use Disorders, and Neurodegenerative Disorders.
Dr Pavlovic is the Editorial Board Member for Neuropsychiatric Disease and Treatment journal and Innovations in Clinical Neuroscience, and is the author of numerous scientific articles published in most eminent psychiatric, neuropsychiatric and psychopharmacological journals, such as the Official Journal of the American Neuropsychiatric Association, Official Journal of the European Psychiatric Association and the Official Journal of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). Furthermore, Dr Pavlovic is the editor of the book "Modulators of Glutamatergic Signaling as Potential Treatments for Neuropsychiatric Disorders," which was published in 2015 by Nova Science Publishers.
Treatments Against Glutamatergic Excitotoxicity in Ischemic Stroke.- Definitions and Concepts of Stress.- Role of Glutamatergic Neurotransmission in the Pathophysiology of Stress-Related Disorders and Chronic Stress Response.- Current Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic Stress and Stress-Related Disorders.- The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments.- Glutamate in Migraine Neurobiology and Treatment.- Astrocyte Glutamate Transporter EAAT2 in Alzheimer Dementia.- The Glutamatergic System as a Target for the Development of New Pharmacological Treatments of Bipolar Disorder.- CNS Glutamate in Impulsive Aggression.- Glutamatergic Treatments for Parkinsons' Disease.- The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression.- Glutamate-Based Treatment for Amyotrophic Lateral Sclerosis/Motor Neuron Disease.- Modulation of Glutamate for Chronic Pain Management.- Pharmacological Role of Glutamate Transporters in Substance Use Disorders.- Glutamate in Multiple Sclerosis: From Pathophysiology to Treatments.- The Role of Glutamate Dysregulation in the Etiology of ADHD.- Glutamate, Glutamatergic Drugs and Schizophrenia.- Glutamate and Epilepsy: An Insight from Temporal Lobe Epilepsy.- Glutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies.- Modulators of Glutamatergic Signaling as Potential Treatments for Autism Spectrum Disorders.
| Erscheinungsdatum | 12.04.2022 |
|---|---|
| Zusatzinfo | XXXV, 600 p. 43 illus., 40 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Gewicht | 1112 g |
| Themenwelt | Medizin / Pharmazie ► Studium |
| Naturwissenschaften ► Biologie ► Humanbiologie | |
| Schlagworte | Aggression • Alzheimer's disease • Amyotrophic lateral sclerosis • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disease • Bipolar Disorders • chronic pain • Chronic Stress and Resilience • drug development • Epilepsy • Glutamate Signaling • ischemic stroke • migraine • Multiple Sclerosis • Parkinson's Disease • Psychopharmacology • Schizophrenia |
| ISBN-10 | 3-030-87479-6 / 3030874796 |
| ISBN-13 | 978-3-030-87479-7 / 9783030874797 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
